Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Cholangiocarcinoma 4Biliary Tract Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Gallbladder Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Basal Cell 1Bile Duct Neoplasms 1Advanced Rectal Cancer 1

Interventions

Bevacizumab 13atezolizumab 9Specimen Handling 9durvalumab 8Nivolumab 7Magnetic Resonance Spectroscopy 7tremelimumab 6lenvatinib 6cabozantinib 4Sorafenib 4tislelizumab 3donafenib 3X-Rays 3Surgical Procedures, Operative 3Oxaliplatin 3Ipilimumab 3Immunotherapy 3Fluorouracil 3ulixertinib 2sintilimab 2sapanisertib 2relatlimab 2pembrolizumab 2camrelizumab 2apatinib 2Leucovorin 2Irinotecan 2Fluorodeoxyglucose F18 2Doxorubicin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Folfox protocol × 30 days × Clear all
NCT05099848 2026-05-22

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Completed
21 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡